Nanomedicine, published by Future Medicine Ltd, is a premier academic journal dedicated to the rapidly evolving field of nanotechnology in medicine. With an emphasis on innovative research and applications, this journal encompasses a broad spectrum of topics including bioengineering, biomedical engineering, and nanoscience, among others. Featuring an impressive Q1 ranking in Development and multiple Q2 rankings across significant categories, it serves as a pivotal resource for researchers and professionals aiming to stay at the forefront of advancements in these disciplines. While the journal is not open access, it is accessible through various institutional subscriptions, ensuring wide dissemination of cutting-edge findings. Notably, it has achieved substantial impact within the scientific community, indicated by its high rankings in Scopus and overall commitment to enhancing the understanding and application of nanomedicine. This journal is a vital conduit for fostering collaborations and innovations that transcend traditional medical paradigms.

Nano LIFE, published by World Scientific Publishing Company, is a multidisciplinary journal that delves into the dynamic fields of bioengineering, biomedical engineering, and pharmaceutical science, providing a platform for researchers to disseminate their cutting-edge findings. With an ISSN of 1793-9844 and e-ISSN 1793-9852, this journal emphasizes the significance of nanoscale research in healthcare and technology, positioning itself as a vital resource for professionals and academics alike. Although currently categorized in the Q4 quartile for multiple scientific disciplines in 2023, its unique focus on the intersection of nanotechnology and life sciences aims to elevate the discourse in these rapidly evolving sectors. Researchers can anticipate publishing innovative methodologies and results, contributing to the overall understanding and application of nanotechnology in medicine. Located in Singapore, Nano LIFE not only serves the global research community but also reflects the growing interest in nanotechnology across diverse fields.

JOURNAL OF MATERIALS SCIENCE-MATERIALS IN MEDICINE is a leading peer-reviewed journal published by Springer, dedicated to advancing the field of biomedical materials science. With an ISSN of 0957-4530 and E-ISSN 1573-4838, this Open Access journal has been committed to providing researchers and professionals with freely accessible, high-quality research since 2021. It features an extensive scope spanning bioengineering, biomaterials, biomedical engineering, and biophysics, reflecting its significant impact within these interdisciplinary domains. Recognized within the Q2 category of the 2023 rankings in multiple fields, the journal proudly positions itself as a crucial resource for innovative materials that contribute to advancements in medical applications. With impressive Scopus rankings, including 26th in Biophysics and 40th in Materials Science for Biomaterials, researchers, students, and industry professionals alike can rely on this publication for cutting-edge insights that drive the future of medical materials and technologies. Based in Dordrecht, Netherlands, the journal provides a vibrant platform for sharing groundbreaking discoveries and fostering collaborative research among a global audience.

Microfluidics and Nanofluidics is a distinguished academic journal published by Springer Heidelberg, focusing on the rapidly evolving fields of micro and nanotechnology. With a commitment to disseminating cutting-edge research, this peer-reviewed journal aims to bridge the gap between fundamental science and practical application within Condensed Matter Physics, Materials Chemistry, and Nanoscience and Nanotechnology. It holds an influential position in its field, reflected by its Category Quartiles (Q3) and notable Scopus Rankings, including a ranking of #145 in Condensed Matter Physics. Researchers, professionals, and students will find this journal to be an invaluable resource for accessing pioneering studies, methodologies, and innovative technologies essential for advancing knowledge and applications in micro and nanofluidics. With an extensive history from 2004 to 2024, Microfluidics and Nanofluidics continues to foster discussion and collaboration within the scientific community, solidifying its role as a leading platform for scholarly communication in this dynamic discipline.

Nanomedicine-Nanotechnology Biology and Medicine is a leading journal published by Elsevier, dedicated to the exploration of innovative applications of nanotechnology in the fields of biology and medicine. With an ISSN of 1549-9634 and an E-ISSN of 1549-9642, this esteemed journal provides a platform for high-quality research, comprehensively covering areas including bioengineering, biomedical engineering, pharmaceutical science, and nanoscience. Notably, it holds a significant position in various categories with a Q2 ranking in multiple disciplines and a prestigious Q1 ranking in Pharmaceutical Science, emphasizing its impact within the scientific community. By facilitating access to cutting-edge studies and advancements, Nanomedicine-Nanotechnology Biology and Medicine serves as an essential resource for researchers, professionals, and students alike, contributing significantly to the ongoing development of nanomedicine and its pivotal role in improving healthcare outcomes. The journal operates without open access; however, it remains committed to disseminating valuable knowledge to a global audience.

Cancer Research and Treatment is a premier academic journal published by the Korean Cancer Association that focuses on advancing scientific knowledge and clinical practices in the fields of cancer research and oncology. With an ISSN of 1598-2998 and an E-ISSN of 2005-9256, the journal showcases cutting-edge research articles, clinical trials, and comprehensive reviews that address the multifaceted challenges in cancer treatment and management. Published in South Korea, this journal has established itself as a critical resource, evidenced by its Q1 rank in Oncology and Q2 rank in Cancer Research, reflecting its influence and stature within the academic community. The impact of research disseminated through Cancer Research and Treatment is underscored by its significant percentile rankings in Scopus, with notable positions in both the pharmaceutical and biological sectors. This journal aims to bridge the gap between laboratory research and clinical application, providing a platform for researchers, healthcare professionals, and students to enhance their understanding of cancer-related innovations and therapeutic strategies. Readers will benefit from rich content that not only discusses the latest advancements but also engages with pressing global health issues related to cancer.

Theranostics is a premier journal in the field of Medicine and Pharmacology, published by IVYSPRING INT PUBL. With its commitment to open access since 2011, it facilitates the widespread dissemination of innovative research, fostering collaboration and advancements in therapeutic diagnostics. The journal proudly holds a Q1 ranking in both Medicine (Miscellaneous) and Pharmacology, Toxicology and Pharmaceutics, as of 2023, showcasing its esteemed position within the scientific community. Recognized globally, it ranks in the top 1%, with Scopus rankings placing it as 4th out of 398 in Medicine and 1st out of 43 in Pharmacology. Theranostics serves as a crucial platform for researchers, professionals, and students to explore cutting-edge developments as it converges multidisciplinary approaches to enhance patient care and treatment efficacy. With a focus on bridging experimental research and clinical applications, the journal is instrumental in shaping future therapies and diagnostic strategies.

European Journal of Medicinal Chemistry, a premier publication by Elsevier France-Editions Scientifiques Médicales Elsevier, has been at the forefront of advancing medicinal chemistry since its inception in 1974. With an impressive impact factor and ranking in the Q1 quartile across multiple categories including Drug Discovery, Medicine (miscellaneous), Organic Chemistry, and Pharmacology, this journal delivers cutting-edge research and reviews that are vital for researchers and professionals in the field. The journal’s scope encompasses the design, synthesis, and evaluation of biological activity of bioactive compounds, making it a critical resource for those looking to innovate in drug development and therapeutic strategies. Although currently not open access, subscribers can benefit from its diverse range of high-quality articles, ensuring the dissemination of knowledge in the ever-evolving landscape of medicinal chemistry. The European Journal of Medicinal Chemistry continues to play a pivotal role in shaping the future of pharmacological research and its application, thus appealing to an audience dedicated to making impactful scientific contributions.

CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS is an esteemed academic journal published by BEGELL HOUSE INC, focusing on the innovative field of drug delivery systems and therapeutic carriers. With an ISSN of 0743-4863 and E-ISSN 2162-660X, this journal serves as a pivotal resource for researchers, professionals, and students engaged in pharmaceutical sciences and pharmacology. Spanning from 1984 to 2024, it has sustained its relevance in an evolving landscape, holding a commendable Q2 ranking in both Medicine (miscellaneous) and Pharmaceutical Science, as well as a Q3 ranking in Pharmacology for 2023. The journal is well-regarded for its critical and comprehensive reviews that enhance understanding and drive advancements in therapeutic applications. Access options are variable, providing insights into contemporary practices and innovations that shape drug delivery strategies. With a strong emphasis on interdisciplinary approaches, CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS not only fosters scholarly dialogue but also propels forward the critical field of therapeutic delivery, making it a valuable asset for anyone looking to deepen their knowledge and influence within this dynamic area of study.

Nanomedicine Journal, published by Mashhad University of Medical Sciences, serves as a vital platform for research and developments in the dynamic field of nanotechnology applied to medicine. With an ISSN of 2322-3049 and an E-ISSN of 2322-5904, this Open Access journal, operational since 2013, makes cutting-edge research freely accessible to encourage collaborative efforts in this rapidly evolving domain. The journal navigates various areas, including bioengineering, biomedical engineering, materials science, and pharmacology, holding prestigious rankings in categories relevant to these fields. The 2023 Scopus Rankings reveal its significant standing within the scientific community, particularly with a 76th percentile in general medicine. By bridging the gap between laboratory technologies and clinical applications, the Nanomedicine Journal aims to empower researchers, professionals, and students alike to contribute to the innovative landscape of nanomedicine. With a convergence period extending from 2019 to 2024 and an established reputation, this journal is essential for those pursuing advancements in therapeutic solutions and diagnostics through nanotechnology.